Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Citi
Colorcon
Fish and Richardson
Farmers Insurance
Cerilliant
Dow

Generated: February 17, 2019

DrugPatentWatch Database Preview

ADDERALL XR 25 Drug Profile

« Back to Dashboard

When do Adderall Xr 25 patents expire, and what generic alternatives are available?

Adderall Xr 25 is a drug marketed by Shire and is included in one NDA. There are four patents protecting this drug.

This drug has ten patent family members in eight countries.

The generic ingredient in ADDERALL XR 25 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Summary for ADDERALL XR 25
International Patents:10
US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 6
Bulk Api Vendors: 1
Clinical Trials: 33
Formulation / Manufacturing:see details
DailyMed Link:ADDERALL XR 25 at DailyMed
Drug patent expirations by year for ADDERALL XR 25
Pharmacology for ADDERALL XR 25

US Patents and Regulatory Information for ADDERALL XR 25

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire ADDERALL XR 25 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-004 May 22, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Shire ADDERALL XR 25 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-004 May 22, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Shire ADDERALL XR 25 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-004 May 22, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Shire ADDERALL XR 25 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-004 May 22, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
UBS
Dow
Johnson and Johnson
Mallinckrodt
Merck
Fuji
McKinsey
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.